nivolumab Nov 28, 2022 NICE Recommends BMS's Opdivo Plus Chemo for HER2-Negative, PD-L1-Positive Gastric Cancer Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Nov 17, 2022 Immunotherapy-Related Myocarditis Caused by Rogue T-Cell Attack, Study Finds Premium Oct 26, 2022 Bristol Myers Squibb Turns in Strong Q3 Opdualag Sales, Growth in CAR T Products Premium Oct 7, 2022 Autoantibody Test Shows It Can Predict Toxicity, Recurrence in Melanoma Patients on Immunotherapy Premium Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Sep 29, 2022 New NIH-Funded Network Aims to Bring Precision to External Beam Radiation Treatment Premium Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Jul 27, 2022 BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles Premium Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jun 4, 2022 At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment Premium May 16, 2022 BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial May 12, 2022 Bristol Myers Squibb Scoops Up Rights to BridgeBio's SHP2 Inhibitor May 5, 2022 Telix Pharmaceuticals Doses First Kidney Cancer Patient in Radiopharmaceutical Trial Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
